Primecap Management Co. CA Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Primecap Management Co. CA decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 404,000 shares of the company's stock after selling 5,290 shares during the quarter. Primecap Management Co. CA owned 0.40% of Neurocrine Biosciences worth $46,549,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter worth approximately $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences during the second quarter valued at about $30,000. New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences during the first quarter worth about $32,000. EdgeRock Capital LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $35,000. Finally, Plato Investment Management Ltd bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at about $41,000. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NBIX. BMO Capital Markets cut their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research note on Thursday, October 17th. Barclays reduced their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a report on Monday, September 9th. Jefferies Financial Group lifted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research report on Monday, August 19th. JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Finally, Oppenheimer raised their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Stock Up 0.5 %

Shares of NBIX stock traded up $0.65 during mid-day trading on Friday, reaching $125.65. 1,206,275 shares of the company's stock traded hands, compared to its average volume of 874,442. The company's 50-day moving average price is $118.55 and its 200-day moving average price is $132.13. The company has a market cap of $12.72 billion, a P/E ratio of 33.51 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $110.52 and a 12 month high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.